source
- Regeneron halts Phase 1/2a uveitis trial of anti-CD3 antibody after safety eventRegeneron announced it is voluntarily ending the Phase 1/2a TITAN study of its anti‑CD3 monoclonal antibody, REGN7041, which was being evaluated for non‑infectious posterior uveitis. The decision…
- Former Legend Biotech CEO Ying Huang appointed head of K2 TherapeuticsK2 Therapeutics announced that Ying Huang, who recently left his role as CEO of Legend Biotech, will now lead the young biotech company. The appointment comes just weeks after Legend announced Huan…